

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Stagg Robert</u> <hr/> (Last) (First) (Middle) C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE <hr/> (Street) REDWOOD CITY CA 94063 <hr/> (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> 03/16/2018	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>OncoMed Pharmaceuticals Inc [ OMED ]</u>	
		<b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) SVP, Clinical R&D	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	47,334 <sup>(1)</sup>	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(2)	12/04/2018	Common Stock	9,000	3.42	D	
Stock Option (Right to Buy)	(2)	07/16/2023	Common Stock	5,000	17	D	
Stock Option (Right to Buy)	(3)	12/17/2024	Common Stock	35,000	21.18	D	
Stock Option (Right to Buy)	(4)	12/26/2025	Common Stock	30,000	21.43	D	
Stock Option (Right to Buy)	(5)	01/02/2027	Common Stock	55,000	7.66	D	
Stock Option (Right to Buy)	(6)	04/22/2027	Common Stock	60,000	3.73	D	
Stock Option (Right to Buy)	(7)	10/06/2027	Common Stock	36,666	4.36	D	
Stock Option (Right to Buy)	(8)	01/03/2028	Common Stock	70,000	3.98	D	

**Explanation of Responses:**

- Includes 45,834 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
- The option is fully vested and exercisable.
- The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of December 18, 2014, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of December 27, 2015, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of January 3, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of April 23, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of October 7, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of January 4, 2018, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

/s/ Alicia J. Hager, Attorney-  
in-Fact for Robert Stagg

03/23/2018

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**